Albireo (NASDAQ:ALBO) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of $3.75 by ($3.90), MarketWatch Earnings reports. The company had revenue of $11.20 million during the quarter, compared to analyst estimates of $55.33 million.
Shares of Albireo stock traded up $32.82 during trading hours on Friday, reaching $32.82. 68,800 shares of the company’s stock were exchanged, compared to its average volume of 69,192. Albireo has a 52-week low of $31.37 and a 52-week high of $31.37. The firm has a market cap of $402.92 million, a PE ratio of -10.42 and a beta of 1.61.
Several institutional investors have recently modified their holdings of the business. Perceptive Advisors LLC raised its position in shares of Albireo by 56.2% in the 4th quarter. Perceptive Advisors LLC now owns 1,320,000 shares of the biopharmaceutical company’s stock worth $33,792,000 after buying an additional 475,000 shares during the period. Federated Investors Inc. PA purchased a new position in shares of Albireo in the 1st quarter worth $10,094,000. Artal Group S.A. purchased a new position in shares of Albireo in the 4th quarter worth $7,680,000. BVF Inc. IL purchased a new position in shares of Albireo in the 1st quarter worth $7,328,000. Finally, Millennium Management LLC raised its position in shares of Albireo by 234.0% in the 1st quarter. Millennium Management LLC now owns 155,611 shares of the biopharmaceutical company’s stock worth $5,068,000 after buying an additional 109,017 shares during the period. 29.35% of the stock is currently owned by institutional investors.
Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate includes A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase II clinical trial for treating progressive familial intrahepatic cholestasis and primary biliary cholangitis.
Receive News & Ratings for Albireo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo and related companies with MarketBeat.com's FREE daily email newsletter.